[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:epithelioid-sarcoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":40,"states":41},"Epithelioid Sarcoma",5,[7,15,22,28,34],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06444880","Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies",[11],"Phase 2","RECRUITING","2026-08-03T03:45:11.273644Z","2026-05-05T02:43:27.586903Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[19],"Phase 1\u002FPhase 2","2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT07089992","A Study of Pembrolizumab in People With Ultra-Rare Sarcomas",[11],"2026-08-26T02:16:48.735701Z","2026-07-05T05:32:16.733886Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT06625190","Alpha\u002FBeta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",[19],"2026-08-26T02:19:04.543908Z","2026-07-05T03:45:20.453806Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":38,"content_modified":39},"NCT04390737","Evaluate the Safety and Clinical Activity of HH2853",[19],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:26.959800Z",[],[]]